Covid: Ema evaluates the ok to Pfizer oral drug

EMA has started to evaluate a marketing authorization application for the oral antiviral medicine Paxlovid. The request is from Pfizer Europe, as the European Medicines Agency says. The result is expected in the coming weeks.

In mid-December, the EMA had given the o to member states to use Pfizer Paxlovid’s antiviral against Covid-19, immediately after the diagnosis of the infection, although the entire review process has not yet been completed for regulatory approval which should arrive shortly.